News

Novum reaches into N. Dakota for clinical trials

CRO Novum has opened its latest hub for clinical trials, expanding into Fargo, ND, in an effort to grow the company's footprint and diversify its offerings.

SRI sets sights on CRO growth with Virginia expansion

Research outfit SRI International is bolstering its CRO division, spending millions to stretch its capabilities and lure more drug development clients to its Virginia labs.

Icon boosts outlook after 19% sales jump

CRO giant Icon is riding high on another spike in revenue, again upping its full-year expectations after increasing profits by more than 50%.

CRO Atheris hooks up with Debiopharm for cancer R&D

Swiss CRO Atheris Laboratories has signed a deal with Debiopharm to help develop a peptide cancer drug, optimizing leads for an innovative venom-derived treatment.

WuXi is first in China with CLIA-OK genomics lab

WuXi PharmaTech won CLIA certification for its Shanghai genomics lab, making it the first such outfit in China to meet U.S. testing standards.

DrugDev picks up CFS Clinical for trial software

U.K. contractor DrugDev has purchased software provider CFS Clinical with plans to merge the company's trial management program with its own investigator network.

Report: Quintiles closes Indian unit over newfound regulatory hurdles

India's ongoing efforts to tighten clinical trial regulations have stirred controversy among researchers around the globe, and now the world's largest CRO has shuttered one of its facilities in the country, citing a tough regulatory climate.

Aenova snags Haupt to boost CMO presence

Germany's Aenova has sealed a deal for contract development and manufacturing outfit Haupt Pharma, a buyout that expands its capabilities and global reach.

Clinlogix buys German CRO with eye on Euro demand

Pennsylvania contractor Clinlogix has bought Germany's ikfe CRO, looking to expand its presence in Europe's market for clinical development.

Novella teams with Scioderm for 'breakthrough' drug

Novella Clinical has snagged its first high-profile partnership since being bought by CRO giant Quintiles, teaming up with biotech Scioderm to manage a mid-stage trial of the company's rare skin disease treatment.

U.K. CRO Cmed expands its U.S. foothold

English CRO Cmed is reaching into Boston and San Francisco, growing its U.S. presence and giving it a front-row seat at two hotbeds of biotech activity.

Quintiles snags registry deal with Muscular Dystrophy Association

Quintiles is lending its research and analytics expertise to the Muscular Dystrophy Association, signing a deal to develop a massive registry of patient data that could help investigators develop new therapies.

Parexel looks to Japan for eClinical growth

Parexel International has inked a deal to pool its clinical trial data management service with a Japanese provider, teaming up to expand its share of the local market.

Icon deepens adaptive trial work with patient-safety service

Irish CRO Icon is riding the spike in demand for adaptive trial monitoring, unveiling a new service that parses study data and highlights potential safety issues in real time.

Yale partners up to run medical device trials

Like many top-tier schools, Yale University has a wealth of expertise and capability in clinical research, and now, citing demand for medical device studies, the Ivy League institution has teamed up with a CRO to land more trial contracts.

Catalent buys up Brazilian CMO with eye on growing market

Catalent has snapped up a Brazilian contract manufacturer, expanding its hold on the global softgel market by growing its presence in Latin America.

Biocon: Syngene is Asia's fastest-growing CRO

Syngene, the CRO arm of Indian biotech giant Biocon, is poised to swell about 20% a year, CEO Kiran Mazumdar-Shaw said, making it the continent's fastest-growing service provider.

Covance launches lab management service to cut study costs

Drug developers look to external labs to do all manners of tests, but they can easily get stretched too thin when trying to manage myriad vendors. Covance is kicking off an external lab management offering, promising to save its clients as much as 65% in oversight costs.

Analyst: Bet on another boom for big CROs

After a booming 2012, the CRO industry is likely to grow even further, one analyst projects, riding an increase in biotech funding and drug development successes.

Boehringer pulls plug on CMO biz, plots 1,100 job cuts

After years of regulatory woes and drug shortages, Boehringer Ingelheim is calling it quits for Ben Venue, planning to shut down its contract manufacturing arm by year's end and lay off about 1,100 workers.